Close Menu
    What's Hot

    Tether Group & Bitfinex Transferred 25,812 BTC To Jack Mallers’ Twenty One Capital

    How to Use Index Funds and ETFs for Passive Crypto Income

    Michael Saylor’s Strategy Announces Initial Public Offering Of 2,500,000 STRD Shares

    Facebook X (Twitter) Instagram
    MarketsNews.co.uk
    • Live Chart
    • Brokers
    • Scam Broker
    • Reviews
    • Tools
      • Lot Size Calculator
      • Margin Calculator
      • PIPS Calculator
      • Profit & loss calculator
    Facebook X (Twitter) Instagram
    Start Trading
    Trending Topics:
    • Markets
    • Stocks
    • Cryptocurrency
    • Forex
    • Scam Broker
    MarketsNews.co.uk
    • Markets
    • Stocks
    • Cryptocurrency
    • Forex
    • Scam Broker
    Stocks

    2 Biotech Stocks To Watch In September 2024

    Anthony M. OrbisonBy Anthony M. OrbisonSeptember 23, 2024No Comments4 Mins Read
    Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
    1727135061 2 Biotech Stocks To Watch In September 2024
    1727135061 2 Biotech Stocks To Watch In September 2024
    Share
    Facebook Twitter LinkedIn Pinterest Email

    The biotech sector represents companies that use biological processes to develop new medicines and treatments. These firms range from small startups to large pharmaceutical giants. Biotech stocks are shares in these innovative companies that trade on public exchanges. The sector is known for its potential to revolutionize healthcare and generate significant returns. However, it’s also associated with high risk due to the complex nature of drug development.

    Investing in biotech stocks can offer exciting opportunities. A successful drug can lead to substantial profits and long-term revenue streams. Biotech companies often become acquisition targets for larger pharmaceutical firms, potentially boosting stock prices. The sector benefits from an aging population and increasing demand for new treatments. However, biotech investments come with considerable risks. Many companies fail to bring products to market. The drug approval process is lengthy, expensive, and uncertain. Biotech stocks can be highly volatile, reacting strongly to clinical trial results.

    When considering biotech stocks, thorough research is crucial. Look at the company’s drug pipeline and the potential market for their treatments. Understand the stages of clinical trials and regulatory hurdles. Consider the company’s cash reserves and ability to fund ongoing research. Be aware that many biotech firms are not yet profitable. Diversification across different biotech companies or subsectors can help manage risk. Remember that biotech investing requires patience and a high tolerance for uncertainty. That said, let’s explore two biotech stocks to watch in the stock market now.

    Biotech Stocks To Buy [Or Avoid] Now

    • Novo Nordisk A/S (NYSE: NVO)
    • Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)

    Novo Nordisk (NVO Stock)

    First up, Novo Nordisk A/S (NVO) is a global healthcare company. They specialize in diabetes care and other chronic diseases, including obesity, hemophilia, and growth disorders. Novo Nordisk is popular for its insulin products and has been expanding its presence in the obesity treatment market.

    This week, Novo Nordisk announced an update on its ongoing share repurchase program. The company is buying back its own B shares as part of a larger DKK 20 billion repurchase plan. Novo Nordisk has been purchasing shares daily since September 2, with varying amounts and prices. As of September 6, the company had repurchased 956,187 B shares under this specific program. In total, Novo Nordisk now owns 13,351,944 B shares as treasury stock, representing 0.3% of its share capital. The company plans to continue this repurchase program, which began in February 2024, for a 12-month period.

    Year-to-date, shares of NVO stock have increased by 27.10% so far. Meanwhile, as of Tuesday’s closing bell, Novo Nordisk stock finished the day down 1.61%, trading at $129.78 a share.

    [Read More] Top Dividend Stocks To Invest In September 2024? 2 To Watch

    Regeneron Pharmaceuticals (REGN Stock)

    biotech stocks to buy (regn stock)

    Second, Regeneron Pharmaceuticals Inc. (REGN) is a biotechnology company that discovers, develops, and commercializes medicines for serious diseases. They focus on areas such as eye diseases, allergic and inflammatory conditions, cancer, and cardiovascular diseases. Regeneron is recognized for its proprietary technologies in drug development, including its VelociSuite® platforms.

    At the beginning of last month, Regeneron Pharmaceuticals reported its second quarter of 2024 financial and operating results. Diving right in, the biotech company announced Q2 2024 earnings of $11.79 per share, with revenue of $3.55 billion. This is compared to analysts’ estimates for the quarter, which were an EPS of $10.62 per share, and revenue estimates of $3.39 billion. Additionally, revenue grew by 12.32% versus the same period, the previous year.

    In 2024, Regeneron Pharmaceuticals shares have gained by 25.56% YTD. Moreover, as of Tuesday’s closing bell, shares of REGN stock finished the day down 0.74%, trading at $1,136.35 a share.

    If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel.
    CLICK HERE RIGHT NOW!!



    Midam Ventures, LLC | (305) 306-3854 | 1501 Venera Ave, Coral Gables, FL 33146 | news@stockmarket.com



    Midam Ventures, LLC | (305) 306-3854 | 1501 Venera Ave, Coral Gables, FL 33146 | news@stockmarket.com



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
    Previous ArticleEthereum surged 15% in 7 days despite whale sell-off
    Next Article DOJ to accuse Visa of illegally monopolizing US debit card market
    Anthony M. Orbison
    • Website

    Related Posts

    President Biden to decide fate of Nippon Steel’s $15 billion bid for US Steel By Reuters

    December 24, 2024

    The true cost of the ’12 Days of Christmas’

    December 24, 2024

    Amicorp Group denies alleged fraud of over $7 billion in Malaysia’s 1MDB scandal By Reuters

    December 24, 2024
    Leave A Reply Cancel Reply

    Amazon.com, Inc.
    $206.65
    $1.64
    0.80%
    Meta Platforms, Inc.
    $670.90
    $23.41
    3.62%
    S&P 500
    $5,935.94
    $24.25
    0.41%
    Alphabet Inc.
    $170.37
    $2.48
    1.43%
    EUR/USD
    $1.14
    $0.0005
    0.05%
    EUR/JPY
    $163.40
    $0.213
    0.13%
    USD/CAD
    $1.37
    $0.0014
    0.10%

    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    We're social. Connect with us:

    Facebook X (Twitter)
    • Home
    • About us
    • Contact
    • Disclaimer
    • Privacy Policy
    © 2025 Marketsnews.co.uk

    Type above and press Enter to search. Press Esc to cancel.